Inhibition of HSP90AA1 by 17-AAG, the first HSP90AA1 inhibitor tested in clinical trials, led to KIT downregulation and cell death in both mutant KIT-expressing mast cells and GIST cell lines [12, 13]. Here, HSP90AA1 is linked to gastrointestinal stromal tumor.